Abstract：
Antibacterial drug resistance of gram-negative bacteria (GNB) results in high morbidity and mortality of GNB infection, seriously threaten human health globally. Developing new antibiotics has become the critical need for dealing with drug-resistant bacterial infections. Cefiderocol is an iron carrier cephalosporin that achieves drug accumulation through a unique \"Trojan horse\" strategy into the bacterial periplasm. It shows high antibacterial activity against multidrug-resistant (MDR) Enterobacteriaceae and MDR non-fermentative bacteria. The application of cefiderocol offers new hope for treating clinical drug-resistant bacterial infections. However, limited clinical data and uncertainties about its resistance mechanisms constrain the choice of its therapeutic use. This review aimed to summarize the clinical applications, drug resistance mechanisms, and co-administration of cefiderocol.
摘要：
革兰阴性菌(GNB)的耐药性导致GNB感染的高发病率和死亡率,严重威胁全球人类健康。开发新的抗生素已成为应对耐药细菌感染的关键需求。头孢地洛是一种铁载体头孢菌素，通过独特的“特洛伊木马”策略将药物积累到细菌周质中。它对多重耐药（MDR）肠杆菌和MDR非发酵细菌显示出高抗菌活性。头孢地洛的应用为临床耐药细菌感染的治疗提供了新的希望。然而,有限的临床数据和其耐药机制的不确定性限制了其治疗用途的选择。本综述旨在总结其临床应用,耐药机制，和头孢地洛的共同管理。
